Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer

F. A. Greco, P. B. Murphy, J. D. Hainsworth, K. R. Hande, D. H. Johnson

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed to test the combination of 21-day oral etoposide with cisplatin in hopes of capitalizing on etoposide's schedule dependency. Sixteen extensive stage SCLC patients were treated with cisplatin 100 mg/m2 day 1 plus 21 days of low-dose oral etoposide 50 mg/m2/day. Chemotherapy was repeated every 28 days for 4 cycles. Blood counts were monitored weekly, and etoposide was discontinued if the leukocyte or platelet count dropped below 2.0 x 109/l or 75 x 109/l, respectively. Fifteen of 16 patients were evaluable for response; 13 achieved either a complete (13%) or partial response (73%), for an overal] response rate of 86% (95% confidence interval, 62-93%). Median response duration was approximately 7 months; median survival was not reached. Thirteen patients (81%) received all the planned cycles of chemotherapy. In cycle 1 of chemotherapy, the median leukocyte nadir was 2.8 x 109/l (range, 0.1-6.3 x 109/l; median platelet nadir was 180 x 109/1 (range, 51-397 x 109/l). Life-threatening leukopenia (< 1.0 x 109/l) was unusual (2 of 58 cycles). There was 1 treatment-related death. One patient developed mild renal insufficiency that resolved after therapy. Nonhematologic toxicities were uncommon, but alopecia occurred in all patients. These data do not suggest that a major survival benefit will be derived for patients with extensive stage SCLC by increasing the duration of etoposide administration when used in combination with cisplatin. A randomized study is needed to determine if this long-term schedule of etoposide plus cisplatin is superior to the standard schedule of etoposide plus cisplatin.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalOncology
Volume49
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1992

Keywords

  • Etoposide
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this